Stock News Releases and Press Releases OTCMKTS, NASDAQ and NYSE Markets

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a best-efforts offering of 10,845,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu ...

PEOPLES FINANCIAL SERVICES CORP. Declares 50.6% Increase in Third Quarter 2024 Dividend PR Newswire SCRANTON, Pa. , July 26, 2024 /PRNewswire/ -- The Board of Directors of Peoples Financial Services Corp. ("Peoples") (NASDAQ: PFIS) declared a third quarter c...

2024-07-26 11:47:23 ET Diversified manufacturer 3M (NYSE: MMM) easily topped Wall Street's quarterly expectations and raised the lower end of its full-year guidance. Investors are rallying into the shares, sending 3M up 17% as of 11:15 a.m. ET. 3M has required patience from ...

Perficient, Inc. (Nasdaq: PRFT) (“Perficient”), the leading global digital consultancy transforming the world’s largest enterprises and biggest brands, today announced it will publish the company’s second quarter 2024 results on Thursday, Aug. 8. Perficient pre...

2024-07-26 11:45:17 ET Image source: The Motley Fool. Centene (NYSE: CNC) Q2 2024 Earnings Call Jul 26, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Centene (CNC) Q2 2024 Earnings Call Transcript

2024-07-26 11:45:00 ET There are few companies on the TSX today that have seen as much success as Celestica ( TSX:CLS ). Celestica stock has established itself as a formidable player in the tech and manufacturing sectors, driving substantial wealth creation for its investors. ...

Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...

TORONTO, July 26, 2024 (GLOBE NEWSWIRE) -- Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) is pleased to report the results of its Annual General and Special Meeting of shareholders held on July 26, 2024 (the "Meeting"). ...

Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...

Kellanova Declares Regular Dividend of $0.57 per Share PR Newswire CHICAGO , July 26, 2024 /PRNewswire/ -- Kellanova (NYSE: K) today announced that its Board of Directors declared a dividend of $0.57 per share on the common stock of Kellanova, payable on...